Literature DB >> 30763667

Mutational analysis of CFTR in the Ecuadorian population using next-generation sequencing.

Juan Carlos Ruiz-Cabezas1, Francisco Barros2, Beatriz Sobrino2, Gustavo García3, Ramiro Burgos4, Carlos Farhat5, Antonella Castro5, Lenin Muñoz5, Ana Karina Zambrano6, Mariela Martínez7, Martha Montalván8, César Paz-Y-Miño6.   

Abstract

The frequency distributions of cystic fibrosis variants are heterogeneous in Ecuador because of the genetic admixture of its population. The aim of this study was to identify disease-causing variants among Ecuadorian cystic fibrosis (CF) patients by next-generation sequencing (NGS) of the entire cystic fibrosis transmembrane conductance regulator (CFTR) gene. The results showed an approximation of the frequencies of pathogenic variants in the population under study and an optimal mutation panel for routine first-line CF molecular diagnosis. One hundred and forty-one patients with suspected CF from the 3 largest Ecuadorian cities (Guayaquil, Quito, and Cuenca) were studied. One hundred and seventy mutated alleles were detected in eighty-five individuals. Twenty-eight disease-causing variants were identified, with p.Phe508del and p.His609Arg being the most frequent (both 24.7%) followed by p.Gly85Glu (11.1%), p.Leu15Pro (9.4%), p.Asn1303Lys (4.1%), and p.Gly542* (2.3%). Together, these variants constituted 76.44% of the detected disease-causing variants. The following six novel potentially disease-associated variants were detected: 3 deletions (CFTR_dele10, CFTR_dele12, and c.2672delA), 1 nonsense variant (p.Cys491*), 1 missense variant (p.Trp496Arg), and 1 complex allele (p.[Gly253Arg;Gly451Val]). The remaining mutations occurred in isolation and were present in the databases.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  CF in Ecuador; CFTR variants; Microarrays; NGS

Mesh:

Substances:

Year:  2019        PMID: 30763667     DOI: 10.1016/j.gene.2019.02.015

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  3 in total

Review 1.  The future of cystic fibrosis care: a global perspective.

Authors:  Scott C Bell; Marcus A Mall; Hector Gutierrez; Milan Macek; Susan Madge; Jane C Davies; Pierre-Régis Burgel; Elizabeth Tullis; Claudio Castaños; Carlo Castellani; Catherine A Byrnes; Fiona Cathcart; Sanjay H Chotirmall; Rebecca Cosgriff; Irmgard Eichler; Isabelle Fajac; Christopher H Goss; Pavel Drevinek; Philip M Farrell; Anna M Gravelle; Trudy Havermans; Nicole Mayer-Hamblett; Nataliya Kashirskaya; Eitan Kerem; Joseph L Mathew; Edward F McKone; Lutz Naehrlich; Samya Z Nasr; Gabriela R Oates; Ciaran O'Neill; Ulrike Pypops; Karen S Raraigh; Steven M Rowe; Kevin W Southern; Sheila Sivam; Anne L Stephenson; Marco Zampoli; Felix Ratjen
Journal:  Lancet Respir Med       Date:  2019-09-27       Impact factor: 30.700

2.  Characterization of Ancestral Origin of Cystic Fibrosis of Patients with New Reported Mutations in CFTR.

Authors:  César Paz-Y-Miño; Ana Karina Zambrano; Juan Carlos Ruiz-Cabezas; Isaac Armendáriz-Castillo; Jennyfer M García-Cárdenas; Santiago Guerrero; Andrés López-Cortés; Andy Pérez-Villa; Patricia Guevara-Ramírez; Verónica Yumiceba; Paola E Leone
Journal:  Biomed Res Int       Date:  2020-05-29       Impact factor: 3.411

3.  Analysis of CNVs of CFTR gene in Chinese Han population with CBAVD.

Authors:  Chengquan Ma; Ruyi Wang; Tengyan Li; Hongjun Li; Binbin Wang
Journal:  Mol Genet Genomic Med       Date:  2020-09-19       Impact factor: 2.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.